| Literature DB >> 16580560 |
C T Thomas1, A Ammar, J J Farrell, H Elsaleh.
Abstract
Many radiosensitizers are in current clinical use. In addition, a myriad of potential new targeted therapies, which may also interact with radiation, are in clinical development. The clinical utility of new targeted therapies, in combination with existing radiation sensitizers (chemotherapies) requires further evaluation, as does the understanding of their acute and late radiation effects. Free radical scavengers appear to show promise as radioprotectors, but data for mucoprotection are less convincing.Mesh:
Substances:
Year: 2006 PMID: 16580560 DOI: 10.1016/j.hoc.2006.01.012
Source DB: PubMed Journal: Hematol Oncol Clin North Am ISSN: 0889-8588 Impact factor: 3.722